RARX - Ra Pharmaceuticals, Inc. - SEC Form 4 Insider Trading Screener
32 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
| P | 16 | +1 | -1 | +1 | +78 |
| S | 14 | +1 | -1 | +1 | +78 |
X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2017-05-18 | RARX | Novartis Bioventures Ltd | 10% | S - Sale | $25.50 | -9,019 | 2,409,403 | 0% | -$229,964 | ||||||
| M | 2017-05-16 | RARX | Novartis Bioventures Ltd | 10% | S - Sale | $25.90 | -42,615 | 2,418,422 | -2% | -$1,103,626 | |||||
| M | 2017-02-22 | RARX | Novartis Bioventures Ltd | 10% | S - Sale | $20.96 | -84,615 | 2,461,037 | -3% | -$1,773,164 | 0 | -2 | |||
| D | 2016-10-31 | RARX | Novo A/s | 10% | P - Purchase | $13.00 | +246,154 | 2,031,562 | +14% | +$3,200,002 | 0 | +2 | +1 | +76 | |
| D | 2016-10-31 | RARX | Shah Rajeev M. | Dir | P - Purchase | $13.00 | +161,538 | 1,968,454 | +9% | +$2,099,994 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Ra Capital Management, LLC | Dir | P - Purchase | $13.00 | +161,538 | 2,542,078 | +7% | +$2,099,994 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Weller Harry R | 10% | P - Purchase | $13.00 | +338,462 | 3,490,073 | +11% | +$4,400,006 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Weller Harry R | 10% | S - Sale+OE | $13.00 | -435 | 3,490,073 | 0% | -$5,655 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Morgenthaler Venture Partners IX LP | 10% | P - Purchase | $13.00 | +263,538 | 2,745,846 | +11% | +$3,425,994 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Morgenthaler Venture Partners IX LP | 10% | S - Sale+OE | $13.00 | -340 | 2,745,846 | 0% | -$4,420 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Viswanathan Ravi | 10% | P - Purchase | $13.00 | +338,462 | 3,490,073 | +11% | +$4,400,006 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Viswanathan Ravi | 10% | S - Sale+OE | $13.00 | -435 | 3,490,073 | 0% | -$5,655 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Sandell Scott D | 10% | P - Purchase | $13.00 | +338,462 | 3,490,073 | +11% | +$4,400,006 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Sandell Scott D | 10% | S - Sale+OE | $13.00 | -435 | 3,490,073 | 0% | -$5,655 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Lettmann Jason | Dir | P - Purchase | $13.00 | +393,923 | 4,066,503 | +11% | +$5,120,999 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Lettmann Jason | Dir | S - Sale+OE | $13.00 | -340 | 4,066,503 | 0% | -$4,420 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Mott David M | 10% | P - Purchase | $13.00 | +338,462 | 3,490,073 | +11% | +$4,400,006 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Mott David M | 10% | S - Sale+OE | $13.00 | -435 | 3,490,073 | 0% | -$5,655 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Kolluri Krishna Kittu | 10% | P - Purchase | $13.00 | +338,462 | 3,490,073 | +11% | +$4,400,006 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Kolluri Krishna Kittu | 10% | S - Sale+OE | $13.00 | -435 | 3,490,073 | 0% | -$5,655 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Novartis Bioventures Ltd | 10% | P - Purchase | $13.00 | +84,615 | 2,545,652 | +3% | +$1,099,995 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Novartis Bioventures Ltd | 10% | S - Sale+OE | $13.00 | -339 | 2,545,652 | 0% | -$4,407 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Kerins Patrick J | 10% | P - Purchase | $13.00 | +338,462 | 3,490,073 | +11% | +$4,400,006 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Kerins Patrick J | 10% | S - Sale+OE | $13.00 | -435 | 3,490,073 | 0% | -$5,655 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Baskett Forest | 10% | P - Purchase | $13.00 | +338,462 | 3,490,073 | +11% | +$4,400,006 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Baskett Forest | 10% | S - Sale+OE | $13.00 | -435 | 3,490,073 | 0% | -$5,655 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Barris Peter J | 10% | P - Purchase | $13.00 | +338,462 | 3,490,073 | +11% | +$4,400,006 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Barris Peter J | 10% | S - Sale+OE | $13.00 | -435 | 3,490,073 | 0% | -$5,655 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Barrett M James | 10% | P - Purchase | $13.00 | +338,462 | 3,490,073 | +11% | +$4,400,006 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | Barrett M James | 10% | S - Sale+OE | $13.00 | -435 | 3,490,073 | 0% | -$5,655 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | New Enterprise Associates 13 LP | 10% | P - Purchase | $13.00 | +338,462 | 3,490,073 | +11% | +$4,400,006 | +1 | -1 | +1 | +78 | |
| D | 2016-10-31 | RARX | New Enterprise Associates 13 LP | 10% | S - Sale+OE | $13.00 | -435 | 3,490,073 | 0% | -$5,655 | +1 | -1 | +1 | +78 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |